Discover Biotech Webinar Pharma FDA & EMA ONCOLife Contact

ONCOLife

Targeting RNase H2 Exposes a New Therapeutic Vulnerability in Triple-Negative Breast Cancer

ONCOLife

ALK Mutation Emerges as a Potential Biomarker for Pan-Cancer Immunotherapy Benefit

Clinical Trials

Social Media Misinformation Drives Over 16 Million Americans Toward High Skin Cancer Risk

ONCOLife

Restoring Proteostasis May Boost T Cell Function and Open a New Route for Immunotherapy

Clinical Trials

Phase 3 MagnetisMM-5 Trial Supports Earlier Use of Elranatamab in Relapsed Myeloma

ONCOLife

Real-World Analysis Links Community Oncology Care to Longer Survival in Multi-Cancer

Clinical Trials

Dual Pathway Blockade Achieves 40% Response in Clear Cell Gynaecological Cancer

Clinical Trials

World’s First Nectin-4-Targeting ADC Enters Phase III Trial in Triple-Negative Breast Cancer

ONCOLife Issues

Featured Articles

FDA Grants Fast Track Designation to Dubodencel for Advanced Cutaneous Melanoma

7 May 2026

The FDA has granted Fast Track designation to dubodencel (DOC1021) for unresectable or metastatic cutaneous melanoma. The first-in-class, patient-derived, double-loaded dendritic cell therapy uses tumor lysate and amplified tumor-derived mRNA to stimulate broa...

Trending Articles

Zenocutuzumab Gains NCCN Support as FDA Review Advances in Cholangiocarcinoma

Phase 2 Data Position Trastuzumab Pamirtecan as a Promising Option in Endometrial Cancer

ONCOLife

13 April 2026

Mocertatug Rezetecan Shows Strong Responses in Ovarian and Endometrial Cancers

FDA & EMA

12 April 2026

FDA Grants Priority Review to Ifinatamab Deruxtecan in Pretreated ES-SC Lung Cancer

FDA & EMA

13 April 2026

MD Anderson Study Identifies DPY30 as Therapeutic Target in Pancreatic Cancer

ONCOLife

11 April 2026

Blocking DHODH Helps Triple Combination Overcome Resistance in Lung Cancer

New Strategy Blocks NMD, Unmasks Hidden Tumor Antigens, and Boosts Immunotherapy

ONCOLife

10 April 2026

Neladalkib Reaches FDA Review for TKI-Pretreated ALK+ Non-Small Cell Lung Cancer

FDA & EMA

9 April 2026

New Radio-Theranostic Promises to Broaden Targeted Radiation in Solid Tumors

ONCOLife

4 April 2026

FDA Grants Breakthrough Status to WU-CART-007 for T-Cell Leukemias and Lymphomas

FDA & EMA

1 April 2026

New IHC Biomarker Test Predicts Which Gastric Cancer Patients Benefit from Immunotherapy

Nonviral Gene Delivery Platform Offers Promise for Cancer Treatment and Cell Therapy

ONCOLife

30 March 2026

Immunotherapy Boosts Chemo Cutting Recurrence Risk by 50% in Colon Cancer

ONCOLife

30 March 2026

AI Predicts Chemotherapy Benefit in Breast Cancer Using Routine Pathology Slides

Clinical Trials

30 March 2026

FDA Approves Agilent’s PD-L1 Test to Guide KEYTRUDA Use in Esophageal and GEJ Carcinoma

FDA & EMA

28 March 2026